Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etidronate→

Etidronate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2809-21-4
Molecular formula
C2H8O7P2
Molecular weight
206.03 g/mol
Drug class
Non-nitrogen-containing bisphosphonatebone-resorption inhibitor
Mechanism of action
Binds to hydroxyapatite in bone and inhibits crystal growth and dissolution. At sufficient exposure it is taken up by osteoclasts and suppresses osteoclastic bone resorption; unlike nitrogen-containing bisphosphonates it does not inhibit farnesyl pyrophosphate synthase.
Indications / reported uses
  • Treatment of Paget’s disease of bone
  • Prevention and treatment of heterotopic ossification in selected settings
  • Treatment of hypercalcaemia associated with malignancy in historical or product-specific settings; check current availability and local label

Sources: NLM MeSH — Etidronic acid · US DailyMed — Etidronate disodium · PubMed — Etidronate pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Etidronate Environmental Risk Assessment (ERA) (the Etidronate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.